Clinical Trials
30 trialsAutologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
ON-5001
OncoNano Medicine, Inc.
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University Health Network, Toronto
POPOPO
Seoul National University Hospital
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
GI-HPVT-01
BGI, China
A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis
Ruhr University of Bochum
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
Southern Illinois University
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Masonic Cancer Center, University of Minnesota
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
National Institutes of Health Clinical Center (CC)
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer
NYU Langone Health
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
H. Lee Moffitt Cancer Center and Research Institute
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Cellectar Biosciences, Inc.
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Melphalan in Patients With Neoplastic Meningitis
Duke University
HIPEC ROC I
University Hospital, Bonn
ITOV04
Assistance Publique - Hôpitaux de Paris
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
Light Sciences LLC